TY - JOUR TI - Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer AU - Hsu, Chia-Lin AU - Tsai, Tzu-Hsiu AU - Huang, Chun-Kai AU - Yang, Ching-Yao AU - Liao, Wei-Yu AU - Ho, Chao-Chi AU - Ruan, Sheng-Yuan AU - Chen, Kuan-Yu AU - Shih, Jin-Yuan AU - Yang, Pan-Chyr T2 - Lung Cancer AB -

Abstract

Objectives

Circulating tumor cells (CTCs) are associated with tumor spread, whereas cancer stem cells may be related to drug resistance. However, few studies have analyzed the levels of circulating cancer stem cells (CCSCs) and CTCs in patients with advanced non-small cell lung cancer (NSCLC).

Materials and Methods

Treatment-naïve patients with EGFR-mutated NSCLC who received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy were recruited prospectively. The cell surface vimentin antibody was used for CTC detection and CD133 antibody for CCSC detection. CCSC and CTC levels were measured as cell count per 4 mL of blood, before treatment, after 2 and 12 weeks of treatment, and at disease progression. Data on clinical characteristics and outcomes were also collected.

Results

At diagnosis (n = 29), the median CCSC and CTC levels were 0 (interquartile range, 0–2) and 3 (2–9), respectively. After 12 weeks, the CCSC and CTC levels were lower than those at diagnosis (CCSC: 0 (0−0), p = 0.14; CTC: 1 (0–4), p = 0.048). At disease progression, the median CCSC and CTC levels were 0 (0–1) and 1 (0–2), respectively. Patients with higher CCSC and CTC levels at diagnosis had a numerically shorter progression-free survival.

Conclusion

In patients with EGFR-mutated NSCLC, CCSC and CTC levels became lower after 12 weeks of EGFR-TKI therapy and remained low at disease progression. High pre-treatment CCSC and CTC levels may be associated with a trend towards poor treatment outcomes.

DA - 2021/06/01/ PY - 2021 DO - 10.1016/j.lungcan.2021.04.014 DP - www.lungcancerjournal.info VL - 156 SP - 50 EP - 58 J2 - Lung Cancer LA - English SN - 0169-5002, 1872-8332 UR - https://www.lungcancerjournal.info/article/S0169-5002(21)00155-0/abstract Y2 - 2021/04/28/20:06:34 ER -